Your browser doesn't support javascript.
loading
Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.
Fang, James C; Ewald, Gregory A; Allen, Larry A; Butler, Javed; Westlake Canary, Cheryl A; Colvin-Adams, Monica; Dickinson, Michael G; Levy, Phillip; Stough, Wendy Gattis; Sweitzer, Nancy K; Teerlink, John R; Whellan, David J; Albert, Nancy M; Krishnamani, Rajan; Rich, Michael W; Walsh, Mary N; Bonnell, Mark R; Carson, Peter E; Chan, Michael C; Dries, Daniel L; Hernandez, Adrian F; Hershberger, Ray E; Katz, Stuart D; Moore, Stephanie; Rodgers, Jo E; Rogers, Joseph G; Vest, Amanda R; Givertz, Michael M.
Afiliação
  • Fang JC; Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah.
  • Ewald GA; Washington University School of Medicine, St. Louis, Missouri.
  • Allen LA; University of Colorado School of Medicine, Aurora, Colorado.
  • Butler J; Stony Brook Heart Institute, Stony Brook University School of Medicine, Stony Brook, New York.
  • Westlake Canary CA; School of Nursing, Azusa Pacific University, Azusa, California.
  • Colvin-Adams M; University of Michigan, Ann Arbor, Michigan.
  • Dickinson MG; Spectrum Health, Grand Rapids, Michigan.
  • Levy P; Wayne State University, Detroit, Michigan.
  • Stough WG; Department of Clinical Research, Campbell University College of Pharmacy and Health Sciences, Buies Creek, North Carolina.
  • Sweitzer NK; Sarver Heart Center, University of Arizona, Tucson, Arizona.
  • Teerlink JR; San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California.
  • Whellan DJ; Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania.
  • Albert NM; Nursing Institute and Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
  • Krishnamani R; Advanced Cardiovascular Institute, Middletown, Ohio.
  • Rich MW; Washington University School of Medicine, St. Louis, Missouri.
  • Walsh MN; The Care Group, Indianapolis, Indiana.
  • Bonnell MR; University of Toledo, Toledo, Ohio.
  • Carson PE; Georgetown University and Washington DC Veterans Affairs Medical Center, Washington, DC.
  • Chan MC; University of Alberta, Alberta, Edmonton, Canada.
  • Dries DL; Temple Heart and Vascular Institute, Temple University Hospital, Philadelphia, Pennsylvania.
  • Hernandez AF; Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Hershberger RE; The Ohio State University, Columbus, Ohio.
  • Katz SD; Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York.
  • Moore S; Massachusetts General Hospital, Boston, Massachusetts.
  • Rodgers JE; University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina.
  • Rogers JG; Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Vest AR; Tufts Medical Center, Boston, Massachusetts.
  • Givertz MM; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: mgivertz@partners.org.
J Card Fail ; 21(6): 519-34, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25953697
We propose that stage D advanced heart failure be defined as the presence of progressive and/or persistent severe signs and symptoms of heart failure despite optimized medical, surgical, and device therapy. Importantly, the progressive decline should be primarily driven by the heart failure syndrome. Formally defining advanced heart failure and specifying when medical and device therapies have failed is challenging, but signs and symptoms, hemodynamics, exercise testing, biomarkers, and risk prediction models are useful in this process. Identification of patients in stage D is a clinically important task because treatments are inherently limited, morbidity is typically progressive, and survival is often short. Age, frailty, and psychosocial issues affect both outcomes and selection of therapy for stage D patients. Heart transplant and mechanical circulatory support devices are potential treatment options in select patients. In addition to considering indications, contraindications, clinical status, and comorbidities, treatment selection for stage D patients involves incorporating the patient's wishes for survival versus quality of life, and palliative and hospice care should be integrated into care plans. More research is needed to determine optimal strategies for patient selection and medical decision making, with the ultimate goal of improving clinical and patient centered outcomes in patients with stage D heart failure.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Gerenciamento Clínico / Insuficiência Cardíaca Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Gerenciamento Clínico / Insuficiência Cardíaca Idioma: En Ano de publicação: 2015 Tipo de documento: Article